Asahi Kasei Corp (3407):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Asahi Kasei Corp (3407) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9966
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Asahi Kasei Corp (Asahi Kasei), manufactures, and markets chemical products. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation panels, foundation systems, methyl methacrylate, adipic acid, polyethylene, polystyrene, functional additives, membrane filtration systems, ion-exchange membranes, medical devices and sensors. Its products find application in the fields of chemicals and fibers, electronics, healthcare and construction. Asahi Kasei markets its products under various brand names such as Bemberg, Roica, Eltas, Bemliese, Lamous, Eutec and Precise among others. The company has operational presence in North America, Central and South America, Europe, Asia and Oceania. Asahi Kasei is headquartered in Chiyoda-ku, Tokyo, Japan.

Asahi Kasei Corp (3407) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Asahi Kasei Corp, Medical Devices Deals, 2012 to YTD 2018 9
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Atox Bio Raises USD30 Million in Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 14
Advanced Circulatory Systems Raises US$2 Million In Financing 16
Partnerships 17
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 17
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 18
Evotec Enters into Agreement with Asahi Kasei Pharma 19
Orion Enters into Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 21
SPI Pharma Enters into Co-Marketing Agreement with Asahi Kasei Chemicals 22
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 23
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 24
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 25
Licensing Agreements 26
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 26
Asahi Kasei Enters into Licensing Agreement with Bone Therapeutics 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 29
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 30
Debt Offering 31
TherOx Raises Funds through Private Placement 31
Asahi Kasei Corp – Key Competitors 32
Asahi Kasei Corp – Key Employees 33
Asahi Kasei Corp – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Asahi Kasei Corp, Medical Devices Deals, 2012 to YTD 2018 9
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atox Bio Raises USD30 Million in Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 14
Advanced Circulatory Systems Raises US$2 Million In Financing 16
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 17
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 18
Evotec Enters into Agreement with Asahi Kasei Pharma 19
Orion Enters into Agreement with Asahi Kasei Pharma 20
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 21
SPI Pharma Enters into Co-Marketing Agreement with Asahi Kasei Chemicals 22
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 23
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 24
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 25
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 26
Asahi Kasei Enters into Licensing Agreement with Bone Therapeutics 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 29
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 30
TherOx Raises Funds through Private Placement 31
Asahi Kasei Corp, Key Competitors 32
Asahi Kasei Corp, Key Employees 33
Asahi Kasei Corp, Subsidiaries 35
Asahi Kasei Corp, Joint Venture 37

List of Figures
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Asahi Kasei Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Asahi Kasei Corp (3407):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Comair Limited:企業の戦略・SWOT・財務情報
    Comair Limited - Strategy, SWOT and Corporate Finance Report Summary Comair Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Moneygram International, Inc.:企業のM&A・事業提携・投資動向
    Moneygram International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Moneygram International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • MEC Resources Ltd (MMR):企業の財務・戦略的SWOT分析
    MEC Resources Ltd (MMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Masimo Corp (MASI):企業の財務・戦略的SWOT分析
    Masimo Corp (MASI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sun A. Kaken Co. Ltd.:企業の戦略・SWOT・財務情報
    Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Green’s General Foods Pty Ltd:企業の戦略・SWOT・財務分析
    Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Danish Crown A/S:戦略・SWOT・企業財務分析
    Danish Crown A/S - Strategy, SWOT and Corporate Finance Report Summary Danish Crown A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Saudi Chemical Company (2230):企業の財務・戦略的SWOT分析
    Saudi Chemical Company (2230) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kaneka Corp (4118):企業の財務・戦略的SWOT分析
    Kaneka Corp (4118) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mondi Plc (MNDI):企業の戦略的SWOT分析
    Mondi Plc (MNDI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Ultra Electronics 3Phoenix, Inc.:企業の戦略・SWOT・財務分析
    Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Arla Foods amba:企業の戦略・SWOT・財務情報
    Arla Foods amba - Strategy, SWOT and Corporate Finance Report Summary Arla Foods amba - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Oversea-Chinese Banking Corporation Ltd:企業のM&A・事業提携・投資動向
    Oversea-Chinese Banking Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Oversea-Chinese Banking Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Massachusetts General Hospital:企業のM&A・事業提携・投資動向
    Massachusetts General Hospital - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Massachusetts General Hospital Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Iberdrola SA (IBE)-エネルギー分野:企業M&A・提携分析
    Summary Iberdrola, S.A. (Iberdrola) is an electric utility. The company generates, trades, transmits, distributes and markets electricity and gas. It operates hydroelectric, thermal and nuclear power plants in Spain and other countries. The company also involved in the production of electricity from …
  • DCP Midstream LP (DCP):石油・ガス:M&Aディール及び事業提携情報
    Summary DCP Midstream LP (DCP), formerly DCP Midstream Partners, LP, is a midstream energy company. It gathers, compresses, treats, and processes natural gas; and produces and markets natural gas liquids (NGL). The company also fractionates NGLs, and recovers and sells condensate. DCP transports NGL …
  • Countrywide Plc:企業のM&A・事業提携・投資動向
    Countrywide Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Countrywide Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Q BioMed Inc (QBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Q BioMed Inc (Q BioMed), formerly ISMO Tech Solutions Inc, is a biomedical acceleration and development company. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It develops Man-01, a pre-clinical lead c …
  • Bank of Scotland Plc:企業のM&A・事業提携・投資動向
    Bank of Scotland Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Scotland Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆